PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

PURPOSE: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. PATIENTS AND METHODS: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a double-blind phase III study, included 521 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiroji, Im, Seock-Ah, Masuda, Norikazu, Im, Young-Hyuck, Inoue, Kenichi, Rai, Yoshiaki, Nakamura, Rikiya, Kim, Jee Hyun, Hoffman, Justin T., Zhang, Ke, Giorgetti, Carla, Iyer, Shrividya, Schnell, Patrick T., Bartlett, Cynthia Huang, Ro, Jungsil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560465/
https://www.ncbi.nlm.nih.gov/pubmed/28831437
http://dx.doi.org/10.1200/JGO.2016.008318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560465/
https://www.ncbi.nlm.nih.gov/pubmed/28831437
http://dx.doi.org/10.1200/JGO.2016.008318

Ejemplares similares